PTPN12

Across TCGA pan-cancer cohorts, PTPN12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPN12 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PTPN12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTPN12 expression acts as an unfavorable survival marker.

OV, BRCA, and PRAD are the cancer types where PTPN12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.215	0.541	.027	18	view →
BRCA	OS	Median	All	0.801	0.963	.014	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.435	0.760	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPN12–OV (DFS)

Open the OV breakdown →